ERBB-REZEPTOR-INHIBITOREN

European patent · EP3814341 · In force

Register entry

Publication number
EP3814341
Application number
EP19800509
Kind
European patent with effect for Switzerland and Liechtenstein
Status
In force
Specification
Granted
Filed
May 8, 2019
Published
May 5, 2021
Granted
Mar 20, 2024
Protection ends at the latest
May 7, 2039
Next annual fee due
May 31, 2027
IPC classes
C07D 409/12 (2006.01)
A61P 35/00 (2006.01)
C07D 401/14 (2006.01)
C07D 471/04 (2006.01)
A61K 31/517 (2006.01)
Priority
WO PCT/CN2018/085998 08.05.2018
PCT application
PCT/CN2019/085949 08.05.2019
PCT publication
WO2019/214634 14.11.2019
Filing language
English
Source
Swissreg

History

What the Federal Institute of Intellectual Property published about this title, newest first.

  1. Jun 1, 2026

    Change

    Published in Swissreg on 01.06.2026

  2. Jun 1, 2025

    Change

    Published in Swissreg on 01.06.2025

  3. Jan 29, 2025

    Change

    Published in Swissreg on 29.01.2025

  4. Jun 2, 2024

    Change

    Published in Swissreg on 02.06.2024

  5. Mar 20, 2024

    Granted

    Published in Swissreg on 20.03.2024

  6. Mar 20, 2024

    Agent entered

    Representative
    RENTSCH PARTNER AG, Kirchenweg 8, Postfach, 8034 Zürich

    Published in Swissreg on 20.03.2024

Parties

Holder

DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD.

No. 199 Liangjing Road Zhangjiang Hi-Tech Park, Shanghai 201203, CN

Agent

RENTSCH PARTNER AG

Kirchenweg 8 Postfach, 8034 Zürich

Inventor

YANG, Zhenfan

Shanghai 201203, CN

WANG, Jiabing

Chalfont, Pennsylvania 18914, US

TSUI, Honchung

Shanghai 201203, CN

ZENG, Qingbei

Shanghai 201203, CN

LI, Zhengtao

Shanghai 201314, CN

ZHANG, Xiaolin

Shanghai 201203, CN

ZHONG, Wei

Corona, California 92881, US

The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.